252 related articles for article (PubMed ID: 38275899)
1. Novel Insights in Venous Thromboembolism Risk Assessment Methods in Ambulatory Cancer Patients: From the Guidelines to Clinical Practice.
Drăgan A; Drăgan AŞ
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275899
[TBL] [Abstract][Full Text] [Related]
2. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
3. Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic.
Holmes CE; Ades S; Gilchrist S; Douce D; Libby K; Rogala B; Parenteau E; Cushman M; Holm AK
JCO Oncol Pract; 2020 Sep; 16(9):e868-e874. PubMed ID: 32267798
[TBL] [Abstract][Full Text] [Related]
4. Prediction and Prevention of Cancer-Associated Thromboembolism.
Khorana AA; DeSancho MT; Liebman H; Rosovsky R; Connors JM; Zwicker J
Oncologist; 2021 Jan; 26(1):e2-e7. PubMed ID: 33274815
[TBL] [Abstract][Full Text] [Related]
5. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism.
Liew NC; Alemany GV; Angchaisuksiri P; Bang SM; Choi G; DE Silva DA; Hong JM; Lee L; Li YJ; Rajamoney GN; Suviraj J; Tan TC; Tse E; Teo LT; Visperas J; Wong RS; Lee LH
Int Angiol; 2017 Feb; 36(1):1-20. PubMed ID: 27606807
[TBL] [Abstract][Full Text] [Related]
6. External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.
Spyropoulos AC; Eldredge JB; Anand LN; Zhang M; Qiu M; Nourabadi S; Rosenberg DJ
Oncologist; 2020 Jul; 25(7):e1083-e1090. PubMed ID: 32017293
[TBL] [Abstract][Full Text] [Related]
7. The Application of Current Proposed Venous Thromboembolism Risk Assessment Model for Ambulatory Patients With Cancer.
Abdel-Razeq H; Mansour A; Saadeh SS; Abu-Nasser M; Makoseh M; Salam M; Abufara A; Ismael Y; Ibrahim A; Khirfan G; Ibrahim M
Clin Appl Thromb Hemost; 2018 Apr; 24(3):429-433. PubMed ID: 28183196
[TBL] [Abstract][Full Text] [Related]
8. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
Key NS; Khorana AA; Kuderer NM; Bohlke K; Lee AYY; Arcelus JI; Wong SL; Balaban EP; Flowers CR; Francis CW; Gates LE; Kakkar AK; Levine MN; Liebman HA; Tempero MA; Lyman GH; Falanga A
J Clin Oncol; 2020 Feb; 38(5):496-520. PubMed ID: 31381464
[TBL] [Abstract][Full Text] [Related]
9. Thromboprophylaxis in ambulatory lung cancer treatment.
Cavaliere L
Clin J Oncol Nurs; 2013 Feb; 17(1):74-9. PubMed ID: 23372099
[TBL] [Abstract][Full Text] [Related]
10. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.
Kimpton M; Wells PS; Carrier M
Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Cohort Study of Venous Thromboembolism Rates in Ambulatory Cancer Patients: Association With Khorana Score and Other Risk Factors.
Austin K; George J; Robinson EJ; Scully M; Thomas MR
J Hematol; 2019 Mar; 8(1):17-25. PubMed ID: 32300436
[TBL] [Abstract][Full Text] [Related]
12. [Thromboprophylaxis in ambulatory patients with cancer].
Hart C; Heudobler D; Linnemann B
Dtsch Med Wochenschr; 2020 Feb; 145(3):130-134. PubMed ID: 32018283
[TBL] [Abstract][Full Text] [Related]
13. Decision support systems in clinical practice: The case of venous thromboembolism prevention.
Nazarenko GI; Kleymenova EB; Payushik SA; Otdelenov VA; Sychev DA; Yashina LP
Int J Risk Saf Med; 2015; 27 Suppl 1():S104-5. PubMed ID: 26639683
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
15. VTE risk assessment in cancer. Who needs prophylaxis and who does not?
Ay C; Pabinger I
Hamostaseologie; 2015; 35(4):319-24. PubMed ID: 25740182
[TBL] [Abstract][Full Text] [Related]
16. Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR).
Maxwell WD; Bennett CL
Semin Thromb Hemost; 2012 Nov; 38(8):759-67. PubMed ID: 23111863
[TBL] [Abstract][Full Text] [Related]
17. Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.
Li H; Tian Y; Niu H; He L; Cao G; Zhang C; Kaiweisierkezi K; Luo Q
Front Oncol; 2022; 12():988287. PubMed ID: 36300098
[TBL] [Abstract][Full Text] [Related]
18. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
Kahn SR; Morrison DR; Diendéré G; Piché A; Filion KB; Klil-Drori AJ; Douketis JD; Emed J; Roussin A; Tagalakis V; Morris M; Geerts W
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008201. PubMed ID: 29687454
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps.
Steiner D; Ay C
Best Pract Res Clin Haematol; 2022 Mar; 35(1):101347. PubMed ID: 36030066
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of venous thromboembolism in cancer patients.
Frere C; Doucet L; Farge D
Expert Rev Hematol; 2016 Jun; 9(6):535-9. PubMed ID: 27031534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
